Inovio Pharmaceuticals, Inc. is a clinical stage biotechnology company focused on developing and commercializing DNA medicines to treat and protect against HPV-related diseases, cancer, and infectious diseases. Its product pipeline includes DNA vaccines and DNA-encoded monoclonal antibodies aimed at various conditions, including cervical cancer, glioblastoma, and recurrent respiratory papillomatosis. Inovio operates primarily in the United States and is engaged in research and clinical trials to advance its therapeutic candidates.
